GUJTHEM
Gujarat Themis Biosyn Limited (GUJTHEM) Stock Analysis
Gujarat Themis Biosyn Limited is an Indian pharmaceutical company producing fermentation-based APIs and biosimilars. It manufactures antibiotics and statin intermediates for global pharma customers. The company operates biotech manufacturing in Gujarat. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹388.60
+2.22% 1W | -13.00% 52W
Market Cap
5.1k CR
P/E Ratio
86.2
52W High
₹470.1
52W Low
₹225.1
Div. Yield
0.17%
Beta
0.7
50 DMA
₹389.5
200 DMA
₹359
Profit Margin
28%
Inst. Own.
11.8%
✅ BOUNCE FROM SUPPORT
📈 CONSOLIDATING UP
Fundamentals
Profit & Loss
| Metric | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 36 | 44 | 44 |
| YoY Sales growth | +22% | ||
| Expenses | 22 | 25 | 23 |
| Operating Profit | 14 | 19 | 21 |
| OPM % | 39% | 44% | 48% |
| Other Income | 0 | 1 | 0 |
| Interest | 0 | 2 | 2 |
| Depreciation | 2 | 4 | 4 |
| Profit before tax | 12 | 14 | 15 |
| Tax % | 25% | 24% | 27% |
| Net Profit | 9 | 11 | 11 |
| EPS in Rs | 0.83 | 1.00 | 1.02 |
| Metric | Mar 2026 |
|---|---|
| Sales | 166 |
| Sales growth | |
| Expenses | 90 |
| Operating Profit | 76 |
| OPM % | 46% |
| Other Income | 2 |
| Interest | 3 |
| Depreciation | 13 |
| Profit before tax | 62 |
| Tax % | 25% |
| Net Profit | 47 |
| EPS in Rs | 4.28 |
| Dividend Payout % | 0% |
Shareholding Pattern
Promoters70.87%
FIIs2.95%
DIIs1.17%
Public25.01%
Promoters70.87%
FIIs1.96%
DIIs1.17%
Public26.00%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters70.87%
FIIs1.76%
DIIs1.17%
Public26.18%
Promoters59.33%
FIIs3.80%
DIIs12.65%
Public24.21%
Promoters75.00%
FIIs0.01%
DIIs0.03%
Public24.95%
Promoters70.87%
FIIs1.05%
DIIs0.82%
Public27.26%
Promoters70.87%
FIIs1.91%
DIIs1.17%
Public26.05%
Promoters70.86%
FIIs1.80%
DIIs1.17%
Public26.15%
Promoters59.33%
FIIs3.80%
DIIs12.65%
Public24.21%
GUJTHEM
Holdings Analysis
Key strengths & risk signals
56
Overall
52
Fundamental
60
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (388.6) above 200-day but below 50-day.
WEAK YEAR! Stock declined 13.0% in the last year.
Strengths (4)
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (389.5) is above 200-day average (359.0) - positive signal.
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
UPPER HALF! Trading at 66.7% of 52W range - positive territory.
Fundamental & Technical Analysis
56Overall
52Fundamental
60Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.8% (SLOW, 5/15). Profit CAGR: -7.0% (DECLINING, 2/15).
Profit Margin
9/10
EXCELLENT EFFICIENCY! 28.0% profit margin - company keeps strong profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.17% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.95% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (389.5) is above 200-day average (359.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (388.6) above 200-day but below 50-day.
Trend Pattern
14/20
Current trend: CONSOLIDATING UP
52W Performance
2/10
WEAK YEAR! Stock declined 13.0% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 279,646 vs down days: 286,302. Ratio: 0.98x
RSI
3/5
NEUTRAL! RSI at 50.8 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 66.7% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 2.2% (1 week), -0.1% (1 month), 11.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
GUJTHEM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-14 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUJTHEM | ₹388.60 | 86.2 | 28.0% | 3.8% | -7.0% | -13.0% | 56 | CONSOLIDATING UP | +22.0% | +1.8% | +22.0% | -0.9% |
| MOREPENLAB | ₹99.60 | 29 | 8.2% | 8.4% | 34.9% | +107.6% | 70 | BREAKDOWN | +117.4% | +57.6% | +81.4% | +30.9% |
| IOLCP | ₹201.60 | 29.1 | 7.4% | 1.6% | -0.4% | +112.6% | 60 | BREAKDOWN | +117.0% | +1.1% | +40.1% | +5.1% |
| FDC | ₹372.10 | 19.3 | 13.7% | 6.8% | 13.2% | -4.1% | 71 | BREAKOUT | +72.9% | -62.9% | +21.0% | -14.3% |
| SPARC | ₹205.80 | 4.1 | 84.7% | -45.3% | – | +60.5% | 64 | APPROACHING RESISTANCE | -67.8% | +17.3% | +279.7% | -24.8% |
| INNOVACAP | ₹1,172.40 | 46.4 | 8.8% | 20.1% | 27.5% | +49.6% | 77 | CONSOLIDATING UP | +42.3% | +15.7% | +34.0% | +5.2% |
| BLISSGVS | ₹673.10 | 45.3 | 15.0% | 7.2% | 22.1% | +292.0% | 74 | CONSOLIDATING DOWN | +91.6% | +4.4% | +28.2% | +9.7% |
| SUVEN | ₹277.80 | – | – | -19.3% | – | +52.0% | 55 | CONSOLIDATING DOWN | +6.5% | -87.1% | +33.3% | -66.7% |
Data from TradeAlone · Updated daily
GUJTHEM News
Gujarat Themis Biosyn Limited (gujthem) Q1 FY27: Topline Surges 22%, PAT Improves 22%2026-08-07Gujarat Themis Biosyn Limited Announces Strategic Acquisitions and Expansion Plans2026-06-29Gujarat Themis Biosyn Limited (gujthem) Q4 FY26: Strong Revenue Growth, Margin Expansion, and Strategic Acquisitions2026-05-25
